BioSpace News Archive

Drug Development

MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa

MorphoSys AG announced today that its licensee Janssen Research & Development, LLC (Janssen) initiated a phase 2 clinical study of guselkumab in patients with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease also known as acne inversa.

November 28, 2018
·
6 min read
Drug Development

ACACIA PHARMA ANNOUNCES POSITIVE BARHEMSYS™ RESCUE TREATMENT DATA PUBLISHED IN ANESTHESIOLOGY

Acacia Pharma Group plc announces that data and analyses from its positive Phase 3 clinical trial of BARHEMSYS™ have been published (Habib et al1) in the online edition of the leading peer-reviewed journal Anesthesiology, the official publication of the American Society of Anesthesiologists.

November 28, 2018
·
5 min read
Deals

Galapagos increases share capital through warrant exercises on November 23, 2018

Galapagos NV announces a share capital increase arising from warrant exercises.

November 28, 2018
·
2 min read
Eisai to Present Latest Data on Perampanel at 72nd American Epilepsy Society Annual Meeting

Eisai Co., Ltd. announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 72nd American Epilepsy Society Annual Meeting (AES 2018) to be held from November 30 to December 4, 2018 in New Orleans in the United States.

November 28, 2018
·
2 min read
Genetown

Rheostat Therapeutics Announces $23 Million Series A Financing; To Develop Potential Treatments for Neurodegenerative Diseases

Rheostat Therapeutics today announced the close of a Series A financing round totaling $23 million.

November 28, 2018
·
5 min read
Looking for ways to measure tumour aggression

Tests show an association between how aggressive a tumour is and the levels of sugar and inflammatory proteins in the blood.

November 28, 2018
·
2 min read
Business

Fusion Antibodies plc Interim Report for the six months ended 30 September 2018

Fusion Antibodies plc announces its unaudited interim results for the six months ended 30 September 2018.

November 28, 2018
·
1 min read
Business

Families aid discovery of a sensory processing gene in children with autism

Next step: Developing therapies to restore the gene product

November 28, 2018
·
6 min read
Environmental exposures early in life modify immune responses – effects visible even in adolescence

The prevalence of allergic diseases has increased significantly over the last decades, creating substantial financial and societal burdens. Due to this, researchers are trying to discover new approaches to the prevention and treatment of these diseases.

November 28, 2018
·
4 min read
EU supports F2G Biotech in Austria with EUR 24 million for antifungal research and innovation

EIB financing strengthens F2G´s research and innovation

November 28, 2018
·
4 min read